• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SOFOSBUVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • SOFOSBUVIR chembl:CHEMBL1259059 Approved

    Alternate Names:

    SOFOSBUVIR
    GS-7977
    SOVALDI
    PSI-7977, GS-7977
    GS7977
    PSI-7977
    SOVALDI®
    S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4- DIHYDROPYRIMIDIN-1(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)- (PHENOXY)PHOSPHORYLAMINO)PROPANOATE
    GI-7977
    GI 7977
    ISOPROPYL (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL]METHOXY}(PHENOXY)PHOSPHORYL]AMINO}PROPANOATE
    PSI 7977
    rxcui:1484911
    pubchem.compound:45375808
    chemidplus:1190307-88-0
    chembl:CHEMBL1259059
    drugbank:08934

    Drug Info:

    (0 More Sources)

    Publications:

    Khan AJ et al., 2019, Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy., J Med Virol
    Ramamurthy N et al., 2018, Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C., Hepatology
    O'Brien TR et al., 2017, IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir., Gastroenterology
    O'Brien TR et al., 2017, Race or genetic makeup for hepatitis C virus treatment decisions?, Hepatology
    Akuta N et al., 2017, Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan., J Med Virol
    O'Brien TR et al., 2014, Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C., Open Forum Infect Dis
    Pedergnana V et al., 2019, Impact of <i>IFNL4</i> Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients., J Interferon Cytokine Res
    Backus LI et al., 2018, Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals., Diagn Microbiol Infect Dis
  • SOFOSBUVIR   IFNL4

    Interaction Score: 25.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31260374 30431653 29866411 29534310 29107709 28100007 27357737 25734178


    Sources:
    PharmGKB

  • SOFOSBUVIR   IFNL3

    Interaction Score: 14.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Ledipasvir,Sofosbuvir
    Combination therapy Sofosbuvir,Velpatasvir
    Combination therapy Sofosbuvir,Velpatasvir,Voxilaprevir

    PMIDs:
    30431653 29534310 29107709 28100007 27357737 25734178


    Sources:
    PharmGKB FDA

  • PharmGKB: sofosbuvir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Ramamurthy N et al., 2018, Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C., Hepatology
    Akuta N et al., 2017, Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan., J Med Virol
    O'Brien TR et al., 2017, Race or genetic makeup for hepatitis C virus treatment decisions?, Hepatology

  • TTD: PSI-7977

    • Version: 2020.06.01

    Alternate Names:
    D0D4YZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1259059

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Sofosbuvir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21